4.980
+0.070
+(1.43%)
As of 9:57:53 AM GMT+8. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
250,483,043
244,703,884
218,182,994
193,564,322.642
168,906,684.575
Cost of Revenue
210,972,687
206,366,398
184,563,943
164,644,632.233
141,691,003.901
Gross Profit
39,510,356
38,337,486
33,619,051
28,919,690.409
27,215,680.674
Operating Expense
23,691,463
23,466,618
20,752,577
18,203,556.327
16,961,656.485
Operating Income
15,818,893
14,870,868
12,866,474
10,716,134.082
10,254,024.189
Net Non Operating Interest Income Expense
-1,408,154
-1,798,626
-1,732,289
-1,647,339.875
-2,087,922.116
Pretax Income
10,643,068
9,880,227
8,361,081
6,873,015.392
5,962,890.790
Tax Provision
2,356,658
2,105,224
1,703,152
1,439,454.919
1,476,387.505
Net Income Common Stockholders
3,777,384
3,854,247
3,500,270
3,080,673.318
2,778,655.930
Diluted NI Available to Com Stockholders
3,777,384
3,854,247
3,500,270
3,080,673.318
2,778,655.930
Basic EPS
0.59
0.61
0.56
0.49
0.44
Diluted EPS
0.59
0.61
0.56
0.49
0.44
Basic Average Shares
6,282,510.461
6,282,510.461
6,282,510.461
6,282,510.461
6,283,122.861
Diluted Average Shares
6,282,510.461
6,282,510.461
6,282,510.461
6,282,510.461
6,283,122.861
Rent Expense Supplemental
--
138,610
136,336
--
--
Total Expenses
234,664,150
229,833,016
205,316,520
182,848,188.560
158,652,660.386
Net Income from Continuing & Discontinued Operation
3,777,384
3,854,247
3,500,270
3,080,673.318
2,778,655.930
Normalized Income
5,181,988.960
5,160,646.806
4,463,129.701
3,979,325.828
4,178,085.559
Interest Income
726,543
587,686
721,177
596,150.322
569,501.567
Interest Expense
2,134,697
2,386,312
2,453,466
2,243,490.197
2,657,423.683
Net Interest Income
-1,408,154
-1,798,626
-1,732,289
-1,647,339.875
-2,087,922.116
EBIT
12,777,765
12,266,539
10,814,547
9,116,505.589
8,620,314.473
EBITDA
16,040,635
15,430,904
13,372,988
11,423,106.083
10,680,042.358
Reconciled Cost of Revenue
210,972,687
206,366,398
184,563,943
164,644,632.233
141,691,003.901
Reconciled Depreciation
3,262,870
3,164,365
2,558,441
2,306,600.494
2,059,727.884
Net Income from Continuing Operation Net Minority Interest
3,777,384
3,854,247
3,500,270
3,080,673.318
2,778,655.930
Total Unusual Items Excluding Goodwill
-1,696,662
-1,554,894
-1,102,250
-1,008,770.808
-1,201,179.611
Total Unusual Items
-1,613,033
-1,472,080
-1,017,112
-907,616.466
-705,522.406
Normalized EBITDA
17,653,668
16,902,984
14,390,100
12,330,722.549
11,385,564.764
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-375,686.040
-331,308.194
-224,528.299
-211,272.639
-297,407.186
12/31/2020 - 10/28/2016
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
SHEZF Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
0.4696
-34.83%
CASBF CanSino Biologics Inc.
3.2000
0.00%
0867.HK CMS
7.400
+2.35%
9989.HK Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
4.400
+1.38%
SHPHF Sihuan Pharmaceutical Holdings Group Ltd.
0.0907
0.00%
3692.HK Hansoh Pharmaceutical Group Company Limited
23.100
+2.21%
0897.HK WAI YUEN TONG
0.350
+2.94%
3613.HK Beijing Tong Ren Tang Chinese Medicine Company Limited
8.650
+1.76%
0512.HK GRAND PHARMA
5.780
+2.30%
0460.HK SIHUAN PHARM
0.640
+1.59%